SDRMi

SDRM International (SDRMi) is a clinical-stage biotechnology company focused on developing regenerative medicine therapies using human amnion epithelial cells (hAECs). The company's platform leverages the unique properties of hAECs, which are derived from the placenta and possess stem cell-like characteristics, including low immunogenicity and potent anti-inflammatory and anti-fibrotic effects. SDRMi's lead programs target severe liver diseases such as cirrhosis and acute-on-chronic liver failure, as well as inflammatory conditions like Crohn's disease. By utilizing cells that are typically discarded as medical waste, the company aims to provide scalable and ethically sourced cell therapies for high-unmet-need indications. The company is currently advancing its lead candidate, SDRM-001, through clinical trials in the United States and Japan.